Rites Ltd. share price target

We maintain our recommendation of BUY on the stock.

We roll over our estimates to FY27 and upgrade our recommendation from HOLD to BUY on the stock.

We maintain our HOLD recommendation on the stock.

We maintain our HOLD recommendation on the stock. We await for better entry point.

We maintain our HOLD recommendation on the stock as recent sharp appreciation in the stock price leaves us with no upside. We await for better entry point.

We maintain our HOLD recommendation on the stock and revise our estimates downward for FY24 and FY25 respectively.

we expect the company to post healthy Revenues/EBITDA/APAT growth of 12%/11%/11%CAGR respectively over FY23-25E. However,the recent appreciation in stock price leaves us with little upside and we maintain our HOLD rating on the stock with a TP of Rs 500/share, implying an upside of 2% from the CMP.

We change our recommendation on the stock from a BUY to HOLD as recent appreciation in the stock price leaves no upside potential. We await a better entry point to re-enter the stock.

We maintain our BUY recommendation on the stock with a TP of Rs 450/Share, (Rs 410/Share earlier) implying an upside of 13% from the CMP. We value the company at 16x FY25E EPS (15x earlier).

Company Outlook & Guidance: The management refrained from giving any revenue guidance but expects to maintain their core EBITDA margin and profitability at a healthy growth rate moving ahead. The company expect good export orders in FY24.

Recommendation: We maintain our BUY recommendation on the stock.

We recommend a BUY rating on the stock with a TP of Rs. 405/ share implying an upside of 10% from the CMP.

We revise our earnings estimates for FY23E and 24E and value the company at 15x FY24 EPS (12.5x earlier) to arrive at a TP of Rs 405/share, implying an upside of 10% from the CMP and hence change our rating from HOLD to BUY.

we change our rating from BUY to HOLD. We value the company at 12.5x FY24E EPS to arrive at a target price of Rs 315 /share (Rs 295/share earlier), implying an upside of only 5% from the CMP.